17-aminoandrostanes



United States Patent 3,009,925 I7-AMWOANDROSTANES John C. Bahcock, Kalamazoo Township, Kalamazoo County, Mich, assignor to The Upjohn Company, Kalamazoo, Micln, a corporation of Michigan No Drawing. Filed Dec. 7, 1959, Ser. No. 857,573 18 Claims. (Cl. 260-397) Z CH3 i so O,

wherein X represents the methylene group, the a-hydroxymethylene group, the fi-hydroxymethylene group, or the carbonyl group, and Y represents hydrogen or fluorine, the latter substituent occurring only when X is fi-hydroxymethylene or carbonyl; and Z represents the B-amino group, either primary secondary, or tertiary. Where Z is a substituted amino group, i.e., secondary or tertiary, the substituent is a lower-alkyl group, preferably methyl or ethyl. Substituent Z can occur in the form of conjugate acid salts thereof or quaternary ammonium salts. In the formula, X and Y together can represent a double bond.

We have discovered that compounds of the foregoing formula possess marked anti-fungal properties as a characteristic.

A compound selected from the class defined in the formula above can be incorporated and administered to the animal organism, including birds and mammals, in the form of creams, ointments, tablets, capsules, pills, solutions, suspensions for oral or parenteral use and the like. The compounds are generally characterized by anti-fungal activity which renders them useful for topical, local, or systemic administration. Topically, the compounds are used in a concentration of about 0.1% to 2% in the form of dusting powders, troches, sprays, drops,

suppositories, aqueous or oil dispersions or in the form of ointments, including a petrolatum-type grease base, creams, water-oil emulsions and lotions. For local treatroom they are useful in combating gastro-intertinal fungal infections as well as in mastitis Where fungous infection is present. They can be prepared in unit dosages for systemic use in birds and mammals, including humans, of 50-500 mg. The estimated dosage of such unit forms is l to 4 times per day depending upon the age, weight, and status of the patient. The usual excipients can be used, such as lactose, starch, and the like, and conventional compounding procedures employed using conven- 3,009,925 Patented Nov. 21, 1961 "ice tional binders in the ease of tablets or pills. As will be illustrated below, other coactive ingredients can be added to the formulations such as other anti-fungal, anti-bac terial, and anti-inflammatory agents.

Of the compounds embraced in the formula above, those in which X represents an oxygenated group are novel chemical compounds, i.e., where X equals u-hydroxymethylene, B- hydroxymethylene, or carbonyl. Moreover, those wherein X and Y together represent a double bond are also novel.

Several of the compounds embraced within the formula above are known. For example, 17-aminoandrostane and its hydrochloride are disclosed in U.S. Patent No. 2,292,080. In U.S. Patent No. 2,863,885 of the present inventor, there are disclosed a number of 17fl-amines within the scope of the formula as the reduction derivatives of l7-isonitrosoandrostanes. The detailed preparation by reductive derivation will be disclosed in the following specification.

The compounds of this invention can be prepared in accordance with the following ilow sheets, the various steps of which are illustrated in detail in the preparations and examples which follow. a i

NOE CHs/\ H 1/ CH: OH;

NH: NH: CH I GHa/,\

' CH; I CHs NH =11. NHL'A CH/\ 2 I CHa 1.13 I

CH: CH?I CH mark CH3 arrrooam i i H a VI vn CHa 7 CH8 NHAlk a v LOH: CH3 CH3 N(Alk);A CH3 N(.Alk)g-}IA E l a H CH: NHAlk-HA represents an alkyl group of from 1 to 12 carbon atoms, preferably a lower-alkyl' group of up to 8 carbon atoms', such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and the like. The substituent Alk is likewise an alkyl group of the same range of values as Alk, but which may be the same as or different from Alk.

In Formula IX, the substituent A is a pharmacologically acceptable anion, preferably a halide such as chloride, bromide and iodide. In Formula IX, the substituent group-N(Alk) when connected to the androstane body of Formula IX represents the complementary cation with A. Together the two ions represent a quaternary ammonium compound. The substituent group preferably contains three similar alkyl radicals as defined above. It can contain, however, alternatively two alkyl groups, being the residual alkyl groups of VI, together with a different alkyl group.

The starting materials I are disclosed in US. Patent No. 2,863,885. Upon reduction, as disclosed in the patent, efiected, for example, by reaction of I with lithium in a mixture of ether, isopropyl alcohol and liquid ammonia, there is produced the l7-amino product IV.

Produced concomitantly with IV is the 17a-amino epimer II which also posseses anti-fungal properties of the same kind as the l7fi-amino compounds.

IV, when brought into contact with an acid HA, under conventional salt-forming conditions is converted to the corresponding HA. salt, V. II undergoes the same reaction. IV can be converted to its secondary amino derivative VIII which in turn can be converted to its HA acid salt XI. The conversion of IV to its secondary amino derivative is carried out under conventional conditions via the urethane intermediate VII, prepared from IV by reaction with an alkylchlorocarbonate. This is accomplished by reaction, for example, of IV with the alkyl chlorocarbonate in the presence of a tertiary organic base such as pyridine, lutidine, or collidine. The conversion of VII to VIII is accomplished under conventional conditions for converting amides to amines, i.e., gydreduction, for example, with lithium aluminum by- The tertiary amino derivatives of IV, i.e., VI, can be prepared by conventional amine-alkylating conditions, e.g., by reaction of an alkyl aldehyde with IV in the presence of formic acid, by reaction of IV with an alkyl halide in the presence of a base, or by reaction of IV with a dialkyl-phosphonate in the presence of a base.

The acid salts (X) of VI are prepared by the convcntional salt-forming reactions, i.e., by reaction of VI with a solution of the acid.

The quaternary salts IX can be prepared by reaction of VI with an alkyl halide (Allq-A). The quaternizing reaction is preferably carried out in solution, in particular in a solvent in which both VI' and the organic compound are soluble.

In the formulae of the foregoing flow sheets, substi-tuent X has been described as methylene, u-hYdIOXY- methylene, fl-hydroxymethylenmor carbonyl. When X is carbonyl, I will undergo all the transformations shown methylamino 9a fluoro 5a androstan 11 one and 173 N ,N dimethylamino 9c: fluoro 50c androstanin the flow sheets except that of VII- VIII. To obtain VIII where X is carbonyl, and subsequently XI, it is necessary to employ an alternative secondary amine-forming procedure. The procedure-is known to chemists as the Becker- Decker procedure and. it consists in converting IV to the corresponding imine by reaction with an hydrocarbon (RCHO) aldehyde such as benzaldehyde, in a solvent such as benzene,'if desired, with azeotropic removal of water. The resultingimine, i.e., where the l7 -substituent group is -N=CHR is then alkylated with an alkyl halide to produce the corresponding, ternary imminium salt wherein the 17-substituent group is (Alk)-N=CHR which, when, attached to the androstenebody of Formula IV forms the cation, the anion being the halide derived from the alkyl halide used. The alkylation procedures are carried outby conventional acoaoas processes, preferably by stirring under nitrogen in benzene or ether solution. The ternary imminium salt can then be hydrolyzed to produce VIII under conventional alkaline hydrolysis conditions, 3 e

The novel compounds of this invention represented by Formula A above, as previously stated, possess valuable anti-fungal properties. This activity is illustrated in the following table wherein the tabulated numerical values are the results of standard anti-fungal screening carried out by incorporating the test compound in agar in petri dishes. at concentrations of 1000, 100 and 10 mcg. per ml. and streaking suspensions of fungal pathogens on the agar surface. The degree of inhibition of growth is observed after 72 hours at 28 C. Plain agar controls are also streaked with'the test organisms. The 'values in the substituent columns headed R and R are taken from the formula the flow sheets, and Formula B, which contain an 11- oxygenated substitutent such as fl-hydroxy, a-hydroxy, and keto.

In the examples arealso listed the detailed syntheses of a number of compounds disclosed in the acknowledged prior patent art.

PREPARATION 1 17fi-amin0-50wndr0stane (IV) and its hydrochloride (V) A solution of 7.21 g. of 17-isonitroso5tat-androstane was made up in 360 ml. of acetic acid, and 10 drops of hydrochloric acid were added. To this solution was added 1.5 g. of platinum oxide and the suspension was shaken under an atmosphere of hydrogen for 16 hours. The platinum oxide was then removed by filtration and the filtrate was evaporated to dryness under vacuum. The residual solute was dissolved by stirring in a mixture of 10% aqueous potassium hydroxide covered by a layer of ether. The ethereal layer was separated and treated with 2.5 N hydrochloric acid, whereupon there separated 17B-amino-5a-androstane hydrochloride, a white crystal.- line solid (6.6 g.) melting at 336-354 C. with charring and decomposition. When crystallized from methanol: 2.5 N hydrochloric acid, the compound had a melting point of 343350 C.

Analysis...Calcd. for C I-I CINO: C, 73.16; H, 11.19;

I H N, 4.49. Found: c, 72.91; H, 11.06; N, 4.26,

TABLE L-ANTIFUNGAD ACTIVITIES or 17-AMINO-C1v STEROIDS R1 In; N.a. Rd. 0.1-. at. H.c. 0.11. as. .M.a. 'nr. Cc. M.c. B.b. T.i.

5-011 ,s-Nrn-nol i 10 V 10 10 10 10 10 5-011 a-NHg-HzO 1, 000 1, 000 9) son s-HN, 10 10 10 10 1o 10 ,s-orr at: 100 100 100 10-100 10 10 100 10o 100 s-on fl-N .HCl 10 10400 10-100 10 10 10 100 10 10 a-on a-NHi-HGI 100 1,000 son fi-NHz-HCOgH 1o 10 10 10 H s-Nrn-noi 1o 10 10 10 B-OH B-ITTCHQI 100 100 100 1,000 100 100 100 100 100 -on: s-Nni-noi' m0 100 100 10 10 10 100 100 100 100 100 100 100 H 1mm 10 10 10 1o 10 10 10 10 10 100 10 10 10 /CH: n fl-N\ 100 10 100 10 1o 10 100 100 10 100 100 100 100 on, out 1- l/ H N 100 10 100 100 100 10 10 100 10 10 10-100 10-100 10 The explanation of the abbreviations in the above table are as follows:

N .a.=N ocardia asieroides.

M. -M1c1ospomm cams B. =Blastomyces brasilinsis.

T. =Trichophyton interdigilale.

1 M 10 (Minimum inhibiting concentration, mcg./ml.). I No inhibition.

The following examples illustrate the preparation of the novel androstane compounds of this invention. These compounds comprise those of Formula A, the formulae of 75 below. It had a melting point of 86-90 C The free amine was obtained from the hydrochloride by conventional procedures as described in Example 1,

7 Analysis.-Calcd. for C H N: C, 82.84; H, 12.08; N, 5.09. Found; C, 82.71; H, 12.48; N, 5.25.

EXAMPLE 1 1 7,8-amin-5a-androstan-115-0! (IV), its hydrochloride (V), the 17a-epimer (II), and its hydrochloride ([11) To a solution containing 20 g. of lithium, added as wire, in 1.5 liters of liquid ammonia there was added 20.0 g. of 17-isonitroso-5u-androstan-1lfl-ol dissolved in 180 ml. of isopropanol and 180 ml. dry diethyl. ether. After stirring the solution for 3 hours, an additional 40 ml. of isopropanol was added. The resulting grey suspension was evaporated to dryness and the residue then washed with 1.5 liters of ether. When this ether extract was treated with 40 ml. of 2.5 N hydrochloric acid, l75-amino-5aandrostan-llfi-ol hydrochloride precipitated as crystalline plates (10.20 .g.). It melted at 272-300 C. with decomposition. A sample, recrystallized from ethyl acetate:methanol, melted at 300-304 C. with decomposition.

Analysis.Calcd. for C H 'ClNO-CH OH: C, 66.72; H, 10.64; N, 3.87. Found: C, 66.58; H, 10.49; N, 3.99.

Extended drying at 80-l00 C. gave the non-solvated 17/3-amino-5a-androstan-1lfi-ol hydrochloride.

A suspension of 5.55 g. of the above hydrochloride methanol solvate product in 55 ml. of 10% aqueous pr tassium hydroxide and 200 ml. of ether was stirred until a clear, two-phase solution was obtained. The ethereal layer was separated, washed with water and evaporated to dryness, yielding the free amine as a solid residue. The free amine was crystallized from aqueous methanol as fine fibrous needles that melted at 194196 C. Further recrystallization yielded fine needles melting at 192-193 C.

Analysis.-Calcd. for C19H33NO-1AH2G: c, 77.09; 3

11.33; N, 4.73. Found: C, 77.37, 77.39; H, 11.44, 11.25; N, 4.92.

Extended drying at 80-100 C. under vacuum gave the non-solvated 17fi-amino-5a-androstan-11 8-01.

The ethereal solution of the reduction product remaining after the hydrochloride had been precipitated, above, was washed with water and evaporated to dryness in vacuo to afiord a clear gum. The gum was crystallized from aqueous methanol yielding 10.55 g. of Nix-amino- 5u-androstan-l 118-01 which melted at 85-90 C. A sample, after recrystallization, melted at 91-100" C. with decomposition.

Analysis.Calcd. for C H NO -H O: C, 73.73; H, 11.40; N, 4.53. Found: C, 73.86; H, 10.25; N, 4.46.

Extended drying at 80-100 C. under vacuum afforded the non-solvated 17u-amino-5a-androstan-11 3-01.

This u-amino compound (II) was converted to its bydrochloride salt (M.P. 161.5-165 dec.) by passing hydrogen chloride into an ether solution of the free amine. It was purified by recrystallization from ethyl acetatemormal hexane.

Analysis.-Calcd. for C H ClNO-l /2H O: C, 64.28; H, 10.51; N, 3.95. Found: C, 64.50; H, 10.31; N, 4.10.

Extended drying at 80-100" C. under vacuum afforded the non-solvated 17a-amino-5u-androstan-115-01 hydrochloride.

EXAMPLE 2 I 7B-amino-5a-androstan-I1 -one (IV) Twelve milliliters of ethyl chlorocarbonate was added to an ice-cooled solution of 6.0 g. of 17fi-amino-5eandrostan-lIfi-ol in 60 ml. of pyridine. The mixture was allowed to stand for several hours and was then poured into water, and the resulting mixture extracted with ether. The ether extract was washed with water, dried over magnesium sulfate, and evaporated to dryness. The residue, l7fi-amino-5a-androstan-l15-01, N-carbethoxylate can be purified by chromatography.

, In the pure or crude form, the foregoing N-carbethoxylate is oxidized with chromic oxide and acetic acidunder conditions conventionally employed for the conversion of hydroc ortisone acetate to cortisone acetate. The oxidation produced thus obtained 17fi-amino-5u-androstan-l1- one, N-carbethoxylate, is hydrolyzed with 10-20% aqueous sodium hydroxide in ethylene glycol to afiord 17B- amino-h-androstan-ll-one which can be recovered from the hydrolysis mixture by diluting the reaction mixture with water, extracting thoroughly with ether, washing the ether with dilute acid, basicifying the dilute acid and extracting the product therefrom with ether. Evaporation of the ether alfords a residue of 173-amino-5a-androstanll-one which can be purified by recrystallization from acetonezSkellysolve B hexanes or from aqueous methanol.

EXAMPLE 3 1 7fl-N,N-dim ethy lam inc-5 a-androstan-l 1 19-01 VI) and its hydrochloride (X) A suspension of 5.22 g. of l7fi-amino-5u-androstan- 115-01 of Example 1 in 4.2 ml. of formic acid and 3.6 ml. of formalin (prepared with cooling in ice), was warmed at until the evolution of gas ceased. After 1% hours heating under reflux, the syrup was allowed to cool and was concentrated in vacuum. The residue was taken up in methylene chloride and then washed with saturated aqueous sodium bicarbonate followed by water. The solid which remained when the solvent was removed was recrystallized twice from methanol to afford 1.80 g. of 17,3-N,N-dimethylaminQ-Sa-andmstan-1lfi-ol, M.P. 16l- 164.

One further crystallization from the same solvent afforded an analytical sample, M.P. 1615-163.

Analysis.-Calcd. for C H NO: C, 78.94; H, 11.67; N, 4.38. Found: C, 79.16; H, 11.83; N, 4.52.

The hydrochloride, M.P. 303-304", was prepared by reaction with hydrogen chloride in the manner described in Example 1.

Analysis.--Calcd. for c ,H,,c1No-H,o= C, 67.43; H, 10.86; N, 3.75. Found: C, 67.19; H, 10.64; N, 3.67.

Extensive drying in vacuo at 80-100 afforded an anhydrous sample of the hydrochloride.

EXAMPLE 4 17,B-N,N-dimethylamino-5a-androstan-I15-01, methiodide (IX) Methyl iodide (5 ml.) was added to a solution of 1.86 g. of the tertiary amine of Example 3. Within 30 minutes, glistening crystals began separating. At the end of 15 hours, the solid was collected on a funnel and recrystallized from the monomethyl ether of ethylene glycol to afford 1.06 g. of the quaternary salt, 17fl-N,N-dimethylamino-5a-androstan-11fl-ol, methiodide (IX), M.P. 307- 308".

Analysis.-Calcd. for C H INO: C, 57.25; H, 8.74; N, 3.04. Found: C, 57.23; H, 9.11; N, 3.02.

EXAMPLE 5 17fl-N,N-diethylamino-S-androslan-IIfi-ol VI and methiodide (IX) EXAMPLE 6 17 3mmin0-90:-fluoro-5u-andr0stan-1113-01 (1V) and its hydrochloride 9a-fluoro-I7-isonitroso Sa-andmstan--01 is produced from 9(11)-androsten-17-one by reaction with N-bromoacetamide in aqueous perchloric acid. This reaction produces 9a-bromo-llB-hydroxy-h-androstan-17-one which is in turn treated in accordance with the procedures disclosed in U.S. Patent No. 2,852,511, particularly Examples 4 and 13, i.e., by reaction with potassium acetate in absolute ethanol solution to produce first 95,11B-OXid-5oaandrostan-17-one, and then reacting this 9 8,ll;9-oxide with anhydrous hydrogen fluoride in chloroform solution to produce 9a-fil10rO-l lfl-hydroxyandrostan-17-one. This compound can be converted to 9a-fluoroandrostane11, 17-dione by oxidation with chromic acid in aqueous acetic acid under the conditions conventionally employed for oxidizing hydrocortisone acetate to cortisone acetate.

9a-flll0r0-l IB-hydroXy-Su-andmstan-17-one and 9afiuOro-Sa-androstane-I1,17-dione are converted respectively by reaction with hydroxylamine hydrochloride in pyridine under the conditions of Example 3 of U.S. Patent No. 2,863,885 to produce 9a-fluoro-17-isonitroso- Sa-andrOStan-llfi-Ol and 9a-fluorol7-isonitroso-5a-androstan-II-one, respectively. These two compounds are respectively subjected to catalytic reduction under the conditions of Preparation 1 above to produce l7fl-amino- 9a-fluoro-5a-androstan-1lB-ol and 17B-amino-9u-fluoro- 5a-androstan-11-one, respectively.

EXAMPLE 7 17,3,N,N-dimethylamino-Qa-fluoro-Soz-androstan- 115-01 VI) its hydrochloride (X) and its methiodide (IX) Employing the product of Example 6, 17B-amino-9afluoro-Sa-androstan-llfi-ol, in the process of Example 3 for the amine therein used, there is produced 17fi-N,N- dimethylamino-9u-fluoro-5ot-androstan-115-01 and its bydrochloride, respectively.

The tertiary amine produced in the foregoing paragraph, when substituted in the process of Example 4, for the tertiary amine used therein is productive of 17fl-N,N- dimethylamino-9a-fluoro5a-androstan-1 15-01 methiodide.

EXAMPLE 8 17B-N-methylamino-h-androstane (VIII) and its hydrochloride (XI) Twelve milliliters of ethyl chlorocarbonate was cautiously added to an ice-cooled solution of 6.0 g. of the amine of Preparation 1 in. 60 ml. of pyridine. After 2 hours standing the mixture was poured into water and this extracted with ether. The extract was washed well with water, dried over magnesium sulfate and taken to dryness to afford the urethane (VII) as an amorphous jel like solid. This was purified by chromatography on Florisil synthetic magnesium silicate (elution with 4% acetone :hexane) A clear solution of the urethane obtained above in 200 ml. of tetrahydrofuran was added to a well stirred suspension of 6.0 g. of lithium aluminum hydride in the same solvent. Following 15 hours heating under reflux the reaction mixture was allowed to cool and the excess reagent destroyed with ethyl acetate. Water (12 ml.) and 20% potassium hydroxide (12 ml.) were then added. The gelatinous precipitate was removed by filtration and the filtrates were taken to dryness. The residual gum, 17fi-N-methylamino-5a-androstane, was converted to the. hydrochloride by reaction with hydrogen chloride as in Example 1 above. One crystallization of the hydrochloride salt from methanol:2.5 N-hydrochloric acid afforded 4.36 g., M.P. 306-308" (sealed capillary).

One further crystallization from the same solvent pair gave a pure sample, M.P.-307-310 (sealed capillary).

Analysis.Calcd. for C H ClN-CH OH: C, 70.45; H, 11.26; N, 3.91. Found: C, 70.60; H, 11.59; N, 4.02.

Extensive drying in vacuo at 80-l00 afiorded material free of solvation.

EXAMPLE 9 1 7 fi-N ,N -dimethylamino-5 ix-ana'rostane (VI) A suspension of 5.3 g. of the amine of Preparation 1 in 4.6 ml. of formic acid and 4.0 ml. of formalin was warmed at 60-65 until all eifervescence stopped (1 hour). The solution was then heated under reflux for 1 /2 hours. The excess reagent was removed in vacuum and the residue taken up in ether and methylene chloride. The solution was washed with saturated aqueous sodium bicarbonate and water and dried over magnesium sulfate. The solid which remained on evaporation of the solution was recrystallized from aqueous ethanol to yield 2.70 g. of the tertiary amine, M.P. 89.5-95. Further crystallization from the same solvents afforded a pure sample, M.P. 87-985.

Analysis.Calcd. for C H N: C, 83.10; H, 12.69; N, 4.62. Found: C, 82.96; H, 12.24; N, 4.80. V

The hydrochloride (X), M.P. 281-282" (sealed capillary) was prepared in the manner described above. A

Analysis.Ca1cd. for C21H38C1N%H2OZ C, 71.37; H, 11.26; N, 3.96. Found: C, 71.66; H, 11.62: N, 4.00.

Extensive drying under vacuum at -'100 C. afiord ed material free of solvent.

EXAMPLE 10 1 7,8-N-pmethyZaminO-Sw-andrOStan-II 13-0l (VIII) The free 17/3-amino-5a-androstan-l1 3-01 produced in Example 1 above is substituted in the process of Example 8. The reaction with ethyl chlor'ocarbonate is productive of 17,8 amino 5a-androstan-11fi-ol, N-carbethoxylate (VII). This product when reduced with lithium aluminum hydride in accordance with the procedure of Example 8 is productive of 17/3-N-methylamino- Sa-androstan-l 15-01 which is converted to the hydrochloride as in Example 8.

EXAMPLE l1 Salts of pharmacologically acceptable acids Substitution of sulfuric acid and phosphoric acid successively for hydrogen chloride in the procedures of Example 1, Example 3, and Examples 8 and 9 is productive of, successively, the sulfate and phsophate salts of the product of the respective preparation and examples in place of the hydrochlorides.

EXAMPLE 12 I7fl-N,N-dimethyIaminO-Su-andmstane, methiodide (IX) A solution of 0.70 g. of the tertiary amine of Example 9 in 25 ml. of ethanol and 5 ml. of methyl iodide was allowed to stand 18 hours. At the end of this time the solution was poured into 200 m1. of'ether. There was precipitated the quaternary salt, M.P. 273-278".

A single crystallization from acetonitrile afforded 0.48 g. of long flat needles, M.P. 2815-2835". (dec.).

Analysis.-Calcd. for C H IN; C, 59.31; H, 9.05; N, 3.14. Found: C, 59.29; H, 9.31; N, 3.40.

EXAMPLE 13 Substituting 17-isonitroso-9(11)-androstene, prepared as described in Example 4 of U.S. Patent No. 2,863,885, for 17-isonitroso-5a-androstan-115-01 in the process of Example 1 there is obtained 17/3-amin0-9(1l)-androstene hydrochloride, a crystalline solid. It is converted to 173- amino-9(ll)-androstene as described in Example 1.

EXAMPLE 14 1 7 ,B-N -methy lam in O-Qa-fl uoro-5 u-androst'an-l I B-ol Following the procedure of Example 8, but using 1719'- amino-9a-fluoro-5ot-androstan-l1 3-01 as starting material is productive of 17 3-N-methylamino-9a-fluoro-5a-androstan-llfi-ol and its hydrochloride.

EXAMPLE 15 Substituting 17-isonitroso-5m-androstan l lw-ol, prepared 10,000 scored tablets for oral use, each containing 400 mg. of 17B-dimethylamino-h-androstan-llp-ol hydrochloride, are prepared from the following types and amounts of ingredients:

Grams l7fl-dimethylamino-5a-androstan-11 3-01 hydrochloride 4000 Starch U.S.P 350 Talc U.S.P 250 Calcium stearate 35 The powdered 17,8-dimethylamino-a-androstan-1lp-ol hydrochloride is granulated with a 4% w./v. aqueous solution of methylcellulose U.S.P. (1500 cps). To the dried granulated mixture is added the mixture of the remainder of the ingredients and the final mixture is compressed into tablets of proper weight. The tablets are suitable for the treatment of moderately severe tinea corporis in adults of average weight in a dosage schedule of 1 tablet three times a day. For children (30 to 50 pounds) a half tablet three times a day is adequate.

In a 200 mg. tablet of the above formulation, it is advantageous to add for the treatment of tinea corporis other co-active materials such as other anti-fungal agents (e.g., Griseofulvin, 100-200 mg.), antibacterial agents (e.g., Tetracycline, 125-250 mg; Novobiocin, 125-250 mg; Sulfadiazine, 200-400 mgm.; and the like), and antiinflarnmatory agents (e.g., Prednisolone 5-20 mg.; Methylprednisolone, 2-15 mg.; and the like).

Similarly, 200 mg. scored tablets of l7fl-arnino-5aandrostan-llfl-ol or 17p-amino-5a-androstan-11 3-01 hydrochloride are prepared by substituting in the above formulation 2000 g. of 17 3-amino-5a-androstan-1lfi-ol or 17p-amino-5a-androstan4 ifl-ol hydrochloride for the 4000 g. of 17fi-dimethylamino-S-androstan 1lfi-ol hydrochloride. These tablets are suitable for the treatment of rheumatic, arthritic, and other inflammatory conditions in a dose of %-2 tablets 1-3 times a day.

EXAMPLE 17 Capsules 10,000 two-piece hard gelatin capsules for oral use, each containing 250 mg. of l7fi-amino-5a-androstane hydrochloride, are prepared from the following amounts and types of ingredients:

- Grams l7fi-amino-5a-androstane hydrochloride 2500 Lactose U.S.P 1000 Starch U.S.P 300 Talc U.S.P 65 Calcium stearate 25 12 hydrochloride. These capsules are suitable for the treatment of rheumatic, arthritic, and other inflammatory conditions in a dose of 1-2 capsules 1-3 times per day. For the treatment of moderately severe rheumatic inflammations in adults of average weight, a dose of one capsule, three times a day would be suitable.

EXAMPLE 18 Aqueous suspension An aqueous suspension for oral use containing in each 5 ml. mg. of l7fl-amino-5u-androstan-11fi-ol is prepared from the following types and amounts of ingredients:

17p-amino-5-androstan-l lfi-ol grams-.. 250 Methylparaben U.S.P do 7.5 Propylparaben U.S.P do 2.5 Saccharin sodium do 12.5 Cyclamate sodium (sodium cyclohexylsulfamate) do 2.5 Glycerin milliliters 3000 Tragacanth powder gr-ams 10 Orange oil flavor do 10 RD. and C. orange dye do 7.5 Deionized water q.s. to rnilliliters 10,000

One or two teaspoonfuls (5-10 ml.) administered four times a day is suitable for prevention of conception.

One or two teaspoonfuls (5-10 ml.) administered once a day is suitable for the treatment of rheumatic, arthritic, and other inflammatory conditions.

EXAMPLE 19 Dusting powder A topical dusting powder suitable for the treatment of fungous infections on the foot or on other parts of the body is prepared from the following types and amounts of ingredients:

Grams 17,3-amino-5a-androstane, fine powder (200 mesh)" 10 Zinc stear- 350 Bentonite 640 Two applications of the powder per day to feet infected with moderately severe athletes feet would be suitable course of treatment until symptoms subside.

EXAMPLE 20 Cream 25 kilograms of a topical cream for treating fungous infections of the skin or scalp are prepared from the following types and amounts of materials:

The stearic acid is melted and the isopropyl myristate mixed therein. The finely powdered 17fi-amino-5a-androstan-l lfl-ol is suspended in the mixture. The methylparaben is dissolved in part of the water at about 70 C., and the triethanolamine and propylene glycol are added to the aqueous solution. With constant stirring the aqueous solution is'combined with the 1713-31111110-502- androstan-l 15-01 stearic acid-isopropyl myristate mixture. The combination is stirred until the temperature reaches about 40 C. The perfume is added and any water loss replaced. Stirring is continued until congealing occurs. The cream is assayed for potency and filled into 5 g. tubes. The preparation is suitable for use in the treatment of moderately severe tinea barbae of the face or neck by 13 direct application to infected areas of the skin twice a day.

In the above formulation, it is advantageous to add other coactive materials such as other anti-fungal agents (e.g., Filipi, 0.1-1%; undecylenic acid, 2%; and the like), antibacterial agents (e.g., neomycin sulfate, /2.%; Polymixin, 5000 units/gram of cream; and the like), and anti-inflammatory agents (e.g., fiuorometholone, 0.1- 0.25%; Methylprednisolone, 0.154%; and the like).

Suitable concentrations of the active ingredients of this invention for topical or local use would range from about 0.1 to about 2%.

I claim:

1. An 1l-oxygenated-17 fi-amino 5oz androstane compound having .the following structural formula:

wherein X is a member of the group consisting of a-hydroxymethylene, fi-hydroxymethylene, and carbonyl; Y is a member of the group consisting of hydrogen and fluorine; and X and Y can together constitute a 9(11)-double bond; and Z is a member of the group consisting of primary amino, monoalkyl amino, and dialkyl amino groups,

the acid salts thereof with pharmacologically acceptable acids and the quaternary salts thereof with pharmacolog- 5 ically acceptable anions.

2. 17 8-N,N-dimethylamino-5a-androstan-1 1 5-01.

3. 17fl-N,N-dimethylamino-Sa-androstan-115-01 hydrochloride.

4. 17/3-N,N-dimethylamino-5a-androstan-1lfl-ol, methiodide.

5. 17fl-N,N-dimethylamino-9 11)-androstene.

6. 17ot-amino-5a-androstan-11 8-01.

7. 17 u-amino-5a-androstan-1 1 5-01 hydrochloride.

8. 17,8-amino-5u-androstan-1lfl-ol.

9. 17 8-amino-5a-androstan-1IB-ol hydrochloride.

10. 17fl-amino-5a-androstan-lla-ol.

11. 17B-amino-5a-androstan-1lot-o1 hydrochloride.

12. 17fl-amino-5wandrostan-1l-one.

13. 17/3-amino-5a-androstan-1l-one hydrochloride.

14. l7p-amino-9 l1)-androstene.

15. 17 j3-amino-9( 1l)-androstene hydrochloride.

17. 17fl-amino-9ot-fluoro 5o: androstan-l lfl-ol hydrochloride.

18. 17,3-methy1amino-5 a-androstan-l 151-01.

References Cited in the file of this patent UNITED STATES PATENTS 

1. AN 11-OXYGENATED-17B-AMINO-5A-ANDROSTANE COMPOUND HAVING THE FOLLOWING STRUCTURAL FORMULA: 